New Easton Capital Fund Structure Fits The Times

Easton capital has secured roughly $20 million for a “special situations” fund of unusual design. The new fund is a five-year commitment between general partners and limited partners with the potential for three one-year extensions. Limited partners estimate the average life of a typical venture fund to be roughly 15 years. Easton Capital’s fund will be concluded in half the time.

Venture capitalists might have a flair for recognizing innovation but they haven’t demonstrated a knack for applying it to themselves. The venture model – many complain – needs repair. Yet, VCs, in trying to raise new funds, only tinker with investment strategies without straying far from the traditional 10-year partnership model upon which the industry is built. Easton Capital Investment Group, however, went farther afield than most in creating the prototype for a new type of fund.

The venture firm secured roughly $20 million for a “special situations” fund of unusual design. The new partnership eschews the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JXR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By 

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

More from Business

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JXR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.